Financial Results
Viva Biotech (1873.HK) Announces 2023 Interim Results: Solid Growth in Main Business, Significant Rebound in Profitability
Revenue reached RMB1,142.2 million, representing a year-on-year increase of approximately 3.0%
Jiangsu Recbio Technology Co., Ltd. announced 2023 interim results report and latest progress
Recbio (02179.HK) announced its latest progress and interim results for 2023.
Harbour BioMed Announces 2023 Interim Results
Harbour BioMed announced its interim results for the six months ended June 30, 2023.
United Imaging Healthcare delivers its 2023 Half-Year report, with revenue growth of 26.35% in the first half of 2023
United Imaging Healthcare (SSE:688271), a global innovator in cutting-edge medical imaging and radiotherapy equipment, has unveiled its highly anticipated 2023 half-year report, revealing robust growth.
Gracell Biotechnologies Reports Second Quarter 2023 Unaudited Financial Results and Provides Corporate Update
Gracell Biotechnologies Inc. (NASDAQ: GRCL) (“Gracell” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to developing innovative and highly efficacious cell therapies for the treatment of cancer and autoimmune diseases, today reported second quarter unaudited financial results for the period ended June 30, 2023, and provided corporate updates.
SINOVAC Reports Unaudited First Half of 2023 Financial Results
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2023.
LianBio Reports Second Quarter 2023 Financial Results and Provides Corporate Update
LianBio (Nasdaq: LIAN), a biotechnology company dedicated to bringing innovative medicines to patients in China and other major Asian markets, today reported financial results for the second quarter ended June 30, 2023.
I-Mab Provides Mid-Year 2023 Financial Results, Business and Corporate Updates
I-Mab (Nasdaq: IMAB) (the "Company"), is a global biotechnology company focused on bringing highly differentiated medicines to patients around the world through the discovery, development, and commercialization of novel immunotherapies and biologics for oncology, today announced its financial results for the six months ended June 30, 2023, and provided key business updates.
Everest Medicines to Announce First Half 2023 Financial Results on August 24, 2023
Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative medicines and vaccines, today announced that it will report financial results for the first half of 2023 ended June 30, 2023 and provide a business update on August 24, 2023. The Company will hold a live conference call in English and Mandarin on August 24, 2023 Beijing Time.
I-Mab to Report Mid-Year 2023 Financial Results, Business and Corporate Updates on August 17, 2023
I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of pioneering immunotherapies, today announced that it will report business and corporate updates and financial results for the six months ended June 30, 2023, before the market opens on Thursday, August 17, 2023.
